PMID- 26861858
OWN - NLM
STAT- MEDLINE
DCOM- 20181219
LR  - 20220321
IS  - 1940-1574 (Electronic)
IS  - 0003-3197 (Linking)
VI  - 68
IP  - 1
DP  - 2017 Jan
TI  - Intravenous Enoxaparin Versus Unfractionated Heparin in Elderly Patients 
      Undergoing Primary Percutaneous Coronary Intervention: An Analysis of the 
      Randomized ATOLL Trial.
PG  - 29-39
AB  - Elderly (>/=75 years old) patients with ST-segment elevation myocardial infarction 
      (STEMI) have higher ischemic and bleeding risk compared with those <75 years old. 
      We investigated the efficacy and safety of intravenous (IV) enoxaparin versus IV 
      unfractionated heparin (UFH) in elderly patients undergoing primary percutaneous 
      coronary intervention (PCI) for STEMI. A prespecified analysis of the Acute 
      Myocardial Infarction Treated with Primary Angioplasty and Intravenous Enoxaparin 
      or Unfractionated Heparin to Lower Ischemic and Bleeding Events at Short- and 
      Long-term Follow-up (ATOLL) study was performed examining the 30-day outcomes in 
      the elderly patients. Of the 165 elderly patients in the ATOLL study, 85 patients 
      received IV enoxaparin 0.5 mg/kg and 80 patients received IV UFH. Intravenous 
      enoxaparin did not reduce the primary end point, the main secondary efficacy end 
      point, major bleeding, major or minor bleeding, and all-cause mortality compared 
      with IV UFH. The rate of minor bleeding (5.9% vs 22.8%, P (adjusted) = .01) was 
      significantly lower with IV enoxaparin compared with IV UFH. Intravenous 
      enoxaparin appears to be a safe alternative to IV UFH in primary PCI of the 
      elderly patients with STEMI.
CI  - (c) The Author(s) 2016.
FAU - Liu, Zhenyu
AU  - Liu Z
AD  - UPMC Sorbonne Universites, ACTION Study Group, Institut de Cardiologie, 
      Pitie-Salpetriere Hospital (AP-HP), Paris, France.
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Sciences and Peking Union Medical College, Beijing, China.
FAU - Silvain, Johanne
AU  - Silvain J
AD  - UPMC Sorbonne Universites, ACTION Study Group, Institut de Cardiologie, 
      Pitie-Salpetriere Hospital (AP-HP), Paris, France.
FAU - Kerneis, Mathieu
AU  - Kerneis M
AD  - UPMC Sorbonne Universites, ACTION Study Group, Institut de Cardiologie, 
      Pitie-Salpetriere Hospital (AP-HP), Paris, France.
FAU - Barthelemy, Olivier
AU  - Barthelemy O
AD  - UPMC Sorbonne Universites, ACTION Study Group, Institut de Cardiologie, 
      Pitie-Salpetriere Hospital (AP-HP), Paris, France.
FAU - Payot, Laurent
AU  - Payot L
AD  - UPMC Sorbonne Universites, ACTION Study Group, Institut de Cardiologie, 
      Pitie-Salpetriere Hospital (AP-HP), Paris, France.
FAU - Choussat, Remi
AU  - Choussat R
AD  - UPMC Sorbonne Universites, ACTION Study Group, Institut de Cardiologie, 
      Pitie-Salpetriere Hospital (AP-HP), Paris, France.
FAU - Sabouret, Pierre
AU  - Sabouret P
AD  - UPMC Sorbonne Universites, ACTION Study Group, Institut de Cardiologie, 
      Pitie-Salpetriere Hospital (AP-HP), Paris, France.
FAU - Cohen, Marc
AU  - Cohen M
AD  - Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ, USA.
FAU - Pollack, Charles V Jr
AU  - Pollack CV Jr
AD  - Department of Emergency Medicine, Pennsylvania Hospital, Philadelphia, PA, USA.
FAU - Goldstein, Patrick
AU  - Goldstein P
AD  - Emergency Department, Lille University Hospital, Lille, France.
FAU - Zeymer, Uwe
AU  - Zeymer U
AD  - Medizinische Klinik B, Klinikum Ludwigshafen, Ludwigshafen, Germany.
FAU - Huber, Kurt
AU  - Huber K
AD  - 3rd Department of Medicine, Cardiology and Intensive Care Medicine, Wilhelminen 
      Hospital, Vienna, Austria.
FAU - Vicaut, Eric
AU  - Vicaut E
AD  - ACTION Study Group, Unite de Recherche Clinique, Hopital Lariboisiere (APHP), 
      Paris, France.
FAU - Collet, Jean-Philippe
AU  - Collet JP
AD  - UPMC Sorbonne Universites, ACTION Study Group, Institut de Cardiologie, 
      Pitie-Salpetriere Hospital (AP-HP), Paris, France.
FAU - Montalescot, Gilles
AU  - Montalescot G
AD  - UPMC Sorbonne Universites, ACTION Study Group, Institut de Cardiologie, 
      Pitie-Salpetriere Hospital (AP-HP), Paris, France gilles.montalescot@aphp.fr.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20160209
PL  - United States
TA  - Angiology
JT  - Angiology
JID - 0203706
RN  - 0 (Anticoagulants)
RN  - 0 (Enoxaparin)
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticoagulants/*therapeutic use
MH  - Enoxaparin/administration & dosage/*therapeutic use
MH  - Female
MH  - Fibrinolytic Agents/*therapeutic use
MH  - Hemorrhage/chemically induced
MH  - Heparin/adverse effects/*therapeutic use
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/therapy
MH  - *Percutaneous Coronary Intervention/methods
MH  - Treatment Outcome
OTO - NOTNLM
OT  - aged
OT  - enoxaparin
OT  - heparin
OT  - myocardial infarction
OT  - percutaneous coronary intervention
EDAT- 2016/02/11 06:00
MHDA- 2018/12/20 06:00
CRDT- 2016/02/11 06:00
PHST- 2016/02/11 06:00 [pubmed]
PHST- 2018/12/20 06:00 [medline]
PHST- 2016/02/11 06:00 [entrez]
AID - 0003319716629541 [pii]
AID - 10.1177/0003319716629541 [doi]
PST - ppublish
SO  - Angiology. 2017 Jan;68(1):29-39. doi: 10.1177/0003319716629541. Epub 2016 Feb 9.